PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
UPDATED ANALYSIS OF UNCERTAIN TAX POSITIONS UNDER ASC 740-10 (FIN 48)
PENTERRA PHARMACEUTICALS CORP.
IMPACT OF IRS NOTICE OF PROPOSED ADJUSTMENT
November 20, 2023
FROM:
Leonard Cross, Responsible Partner Garrett Simmons, Lead Associate Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Tel: (215) 555-7400
TO:
Marcus Whitfield, Vice President, Global Tax Penterra Pharmaceuticals Corp. 2200 Independence Boulevard Princeton Junction, NJ 08550
Deborah Staines, General Counsel Penterra Pharmaceuticals Corp. 2200 Independence Boulevard Princeton Junction, NJ 08550
CC:
Sylvia Hartwell, Billing Partner, Calderwood & Harkness LLP Leila Nazari, Working Associate, Calderwood & Harkness LLP
RE: C&H Matter Number 1018-00009 — Updated FIN 48 / ASC 740-10 Reserve Analysis Following Issuance of Notice of Proposed Adjustment (NOPA) dated October 12, 2023
NOTE: This memorandum updates our initial FIN 48 analysis dated September 2022 and is prepared for use by Penterra Pharmaceuticals Corp. ("PPC") and its independent auditor, Crestfield & Associates LLP (Martin Ogilvy, Engagement Partner), in connection with PPC's year-end 2023 financial statement reporting obligations. This memorandum is protected by the attorney-client privilege and the attorney work product doctrine. It should not be disclosed to the Internal Revenue Service, any other taxing authority, or any other adverse party without prior written consent of Calderwood & Harkness LLP.
Right-click to update Table of Contents
I. Executive Summary
On October 12, 2023, the Internal Revenue Service, Large Business & International Division, Northeast Transfer Pricing Practice, Examination Team LB&I-NE-TP-2022-00641 (the "Exam Team"), issued a Notice of Proposed Adjustment ("NOPA") for tax years 2017 through 2020. The NOPA proposes net adjustments of $380.4 million to PPC's transfer pricing positions involving its Irish intellectual-property-holding subsidiary, Penterra Biopharma International DAC ("PBI"). The NOPA was followed by a 30-Day Letter issued November 8, 2023, affording PPC the opportunity to file a formal Protest and request a conference with the IRS Office of Appeals.
PPC currently maintains a pre-settlement uncertain tax position reserve under Accounting Standards Codification 740-10 (formerly FASB Interpretation No. 48, "FIN 48") of $62.4 million related to its Irish intellectual property structure. This reserve was established based on Calderwood & Harkness LLP's ("C&H") initial FIN 48 analysis dated September 2022 and has been carried forward in PPC's financial statements through the third quarter of 2023.
The purpose of this memorandum is to reassess whether the existing $62.4 million reserve remains adequate, requires an increase, or should otherwise be adjusted in light of the NOPA. This reassessment applies the two-step recognition and measurement framework prescribed by ASC 740-10-25 and ASC 740-10-30, respectively, considering the technical merits of PPC's positions, the quality of PPC's contemporaneous transfer pricing documentation, and the range of probable outcomes upon ultimate resolution of the disputed issues.
Summary Conclusion. After a thorough analysis of the NOPA, the underlying IRS positions, PPC's transfer pricing documentation and economic analyses, applicable case law and regulatory authority, and historical IRS Appeals settlement patterns in comparable transfer pricing disputes, C&H recommends that PPC maintain the existing $62.4 million reserve without material adjustment for the year-end 2023 financial statements. In C&H's assessment, the NOPA represents the IRS Exam Team's opening negotiating position and does not reflect the more-likely-than-not outcome of the tax positions at issue. The hazards-of-litigation analysis supports that PPC's transfer pricing positions are more likely than not to be sustained on the merits, and the measurement-step analysis under the cumulative probability approach supports maintaining the current reserve level.
PPC's formal Protest is being prepared by C&H and is scheduled for filing on December 22, 2023. Following the filing of the Protest, the case will be referred to the IRS Office of Appeals for consideration and resolution. C&H anticipates that the Appeals conference will be scheduled in early 2024, and we will reassess the reserve at that time based on any new developments or information arising from the Appeals process.
II. Background
A. PPC's Transfer Pricing Structure
Penterra Pharmaceuticals Corp. ("PPC") is a publicly traded specialty pharmaceutical and biotechnology company incorporated in Delaware and listed on the Nasdaq Global Select Market under the ticker symbol "PPCA" (Employer Identification Number 22-3741856). PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported consolidated revenues of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals globally. PPC's therapeutic focus areas include oncology, immunology, and rare-disease therapeutics.
PPC's key pharmaceutical products and their fiscal year 2020 revenue performance are as follows:
Veritaxol is PPC's flagship oncology product and qualifies as a "Blockbuster" therapeutic with annual global net sales consistently exceeding $3 billion. Imvara and Cerulon represent significant and growing revenue contributors, with Imvara serving as PPC's primary immunology franchise and Cerulon addressing a high unmet-need rare-disease indication.
PPC's international transfer pricing structure centers on Penterra Biopharma International DAC ("PBI"), an Irish-incorporated entity that functions as both an intellectual property holding company and the commercial principal for PPC's non-Americas operations. PBI was incorporated on March 15, 2012 in Ireland, with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4. PBI holds an Irish tax reference number of 3218764T.
PBI is wholly owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a Luxembourg private limited liability company with its registered office at 14, rue Aldringen, L-1118 Luxembourg (RCS Number B 168452). PHL, in turn, is wholly owned by PPC. For United States federal income tax purposes, PHL is treated as a disregarded entity, and PBI is accordingly treated as a controlled foreign corporation ("CFC") of PPC under Subpart F of the Internal Revenue Code.
PBI operates as the intellectual property holding company and principal entity for the commercialization of PPC's pharmaceutical products outside the Americas region. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. As of fiscal year 2020, PBI employed 185 individuals in Ireland, representing a significant increase from the 52 employees at its inception in 2012. The growth in PBI's headcount reflects the deliberate and ongoing expansion of PBI's operational capabilities and commercial functions over the relevant period.
In addition to PBI, PPC's Irish operations include Penterra Manufacturing Ireland Ltd. ("PMI"), a wholly owned subsidiary of PBI incorporated in Ireland. PMI is located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29 (Companies Registration Office Number 512347). PMI operates as a contract manufacturer under a cost-plus arrangement with PBI, providing pharmaceutical manufacturing services at a markup of cost plus 8%. PMI employed approximately 620 individuals during the years at issue and maintains significant pharmaceutical manufacturing infrastructure in Cork, Ireland.
B. Cost-Sharing Arrangement and Legacy IP License
Central to the transfer pricing positions at issue in the NOPA are two intercompany agreements: (i) the Qualified Cost Sharing Arrangement ("CSA") between PPC and PBI, and (ii) the legacy intellectual property license agreement for pre-2012 compounds.
Cost-Sharing Arrangement. The CSA was entered into effective July 1, 2012, under the authority of Treasury Regulation § 1.482-7. Pursuant to the CSA, PBI co-funds PPC's global research and development expenditures in exchange for the exclusive right to exploit resulting intellectual property in territories outside the Americas (i.e., Europe, Middle East, Africa, and Asia-Pacific). PBI's cost-sharing percentage is determined annually based on its share of the reasonably anticipated benefits ("RAB") from the intangible property developed under the CSA, consistent with the requirements of Treasury Regulation § 1.482-7(e).
At the inception of the CSA on July 1, 2012, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC. This PCT payment represented a buy-in for PBI's proportionate share of the pre-existing intangible property contributed by PPC to the CSA, including clinical-stage compounds, development-stage research programs, and associated know-how. The PCT valuation was determined based on a discounted cash flow analysis at the time of the CSA's inception.
PBI's cost-sharing percentages and corresponding cost-sharing payments for the tax years at issue (2017–2020) were as follows:
The gradual increase in PBI's cost-sharing percentage over the four-year period reflects the growth in PBI's non-Americas revenue relative to PPC's Americas revenue, consistent with the RAB methodology prescribed by the CSA and Treasury Regulation § 1.482-7(e).
Legacy IP License. Separate from the CSA, PPC and PBI entered into an intellectual property license agreement for pre-2012 compounds — that is, pharmaceutical products that had been fully developed and commercialized prior to the inception of the CSA and therefore were not subject to the cost-sharing arrangement. Under this license, PBI pays PPC a royalty of 4.5% of net sales for non-Americas sales of legacy compounds.
The legacy compound non-Americas net sales and corresponding royalty payments for the tax years at issue were as follows:
The declining trajectory of legacy compound net sales reflects the natural lifecycle of these older products as they face patent expirations and generic competition in non-Americas markets.
C. Existing FIN 48 Reserve
PPC established an uncertain tax position reserve under ASC 740-10 of $62.4 million related to its Irish intellectual property structure, as supported by C&H's initial FIN 48 analysis dated September 2022. This reserve has been reflected in PPC's consolidated financial statements since the third quarter of 2022 and was carried forward through the most recent quarterly financial statements.
The $62.4 million reserve was computed based on probability-weighted assessments of the potential for an IRS challenge to the following transfer pricing positions:
(a) the CSA cost-sharing ratios applied for all years;
(b) the 4.5% legacy IP royalty rate;
(c) the PCT valuation of $312 million at CSA inception; and
(d) PBI's economic substance as an IP owner and CSA participant.
In establishing the reserve, C&H applied the cumulative probability approach specified by ASC 740-10-30, evaluating the range of possible IRS adjustments and their associated probabilities to determine the largest amount of tax benefit that was greater than 50% likely to be realized upon ultimate settlement.
Contemporaneous transfer pricing documentation was prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) for all four tax years under the requirements of Treasury Regulation § 1.482-7 (for the CSA) and Treasury Regulation § 1.482-4 (for the legacy IP license). This documentation was prepared in compliance with the requirements of Internal Revenue Code § 6662(e)(3)(B), establishing the penalty protection framework applicable to transfer pricing positions supported by contemporaneous documentation.
D. IRS Examination History
The IRS examination of PPC's tax years 2017–2020 commenced with the issuance of a Letter 2205-A (notification of examination) on May 16, 2022. The examination has been conducted by the IRS Large Business & International Division, Northeast Transfer Pricing Practice, under Examination Team designation LB&I-NE-TP-2022-00641. The key IRS personnel assigned to the examination include:
• Gerald Meskill, Supervisory Revenue Agent and Team Manager;
• Patricia Dunleavy, Lead Revenue Agent;
• Dr. Alan Washburne, IRS Economist (Office of the Chief Economist, LB&I Division);
• Franklin Rosario, Attorney-Advisor, IRS Office of Chief Counsel; and
• Donna Hirabayashi, Senior Counsel, IRS Office of Chief Counsel.
Over the course of the examination, the Exam Team issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023, covering PPC's transfer pricing policies, intercompany agreements, CSA documentation, RAB projections, PCT valuation, functional analyses, PBI organizational structure and operations, and comparable company data.
C&H was engaged by PPC to represent it in connection with the examination effective June 2, 2022. In addition, C&H retained Whitmore Valuation Group LLC ("Whitmore") as a consulting expert under a Kovel arrangement effective June 20, 2022 (C&H reference 1018-00009-KV). Whitmore's engagement team is led by Dr. Helena Vasquez, Managing Director, and Dr. Rohan Chakrabarti, Senior Director, both of whom have extensive experience in pharmaceutical transfer pricing valuations and economic analyses. The Kovel arrangement ensures that communications between Whitmore and C&H are protected by the attorney-client privilege.
PPC was not participating in the IRS Compliance Assurance Process ("CAP") for the tax years at issue. Accordingly, the examination followed standard post-filing procedures, and there were no pre-filing agreements or advance pricing agreements in place with respect to PPC's transfer pricing positions.
III. Summary of IRS Notice of Proposed Adjustment (October 12, 2023)
On October 12, 2023, the Exam Team issued the NOPA proposing aggregate net adjustments of $380.4 million to PPC's taxable income for tax years 2017 through 2020. The NOPA adjustments are organized into three principal categories, each of which is discussed below. A 30-Day Letter was subsequently issued on November 8, 2023, affording PPC the opportunity to file a formal Protest within 30 days.
A. CSA Cost-Sharing Ratio Adjustments — $235.01 Million
The IRS proposes increasing PBI's cost-sharing percentage under the CSA by approximately 8 to 12 percentage points in each of the four tax years at issue. The IRS's position is that PPC's projections of reasonably anticipated benefits understated the value of U.S.-source intangible development activities and, correspondingly, overstated the share of anticipated benefits attributable to PBI's non-Americas exploitation rights. In the Exam Team's view, PBI should have borne a larger share of the annual R&D cost pool to reflect the greater proportion of value created by PPC's U.S.-based research and development activities.
The specific proposed adjustments to the CSA cost-sharing percentages and the resulting additional cost-sharing payments are as follows:
The IRS economist, Dr. Alan Washburne, prepared an economic analysis supporting the revised cost-sharing percentages. C&H and Whitmore have reviewed Dr. Washburne's analysis and identified significant methodological deficiencies, which are discussed in detail in Section V.A below. In C&H's assessment, the proposed increases of 10.0 to 11.2 percentage points are not supported by sound economic analysis and reflect an aggressive interpretation of the reasonably anticipated benefits framework under Treasury Regulation § 1.482-7(e).
B. Royalty Rate Adjustments — $188.04 Million
The IRS proposes increasing the legacy IP royalty rate from PPC's position of 4.5% of non-Americas net sales to 11.0% of non-Americas net sales. The IRS's position is based on a comparable uncontrolled transaction ("CUT") analysis utilizing third-party pharmaceutical licensing agreements that, in the Exam Team's view, more accurately reflect the arm's-length royalty rate for the licensed pre-2012 compounds.
The specific proposed royalty rate adjustments and resulting additional royalty income allocable to PPC are as follows:
C&H has significant concerns regarding the comparability of the CUT data relied upon by the Exam Team, as discussed in Section V.B below. The IRS's proposed 11.0% royalty rate falls well outside the interquartile range established by PPC's CUT analysis and relies on license agreements that C&H and Whitmore believe are distinguishable from PPC's legacy IP license on multiple comparability dimensions.
C. Economic Substance Challenge
In addition to the specific numerical adjustments to the CSA cost-sharing ratios and the royalty rate, the NOPA asserts that PBI lacked sufficient economic substance to justify its role as the IP owner and CSA participant. The Exam Team contended that key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions remained concentrated in the United States at PPC's Princeton Junction headquarters and its U.S.-based research facilities, and that PBI's Irish operations were insufficient to support PBI's claimed status as an independent IP owner and commercial principal.
This economic substance position underpins both the CSA and royalty adjustments and, if sustained by a court, could support a full recharacterization of the intercompany arrangements such that all income from the exploited IP would be treated as earned by PPC in the United States. C&H addresses the strength of PBI's economic substance position in detail in Section V.C below.
D. PCT Undervaluation (Background)
The Exam Team further asserted that PBI's PCT payment of $312 million at the inception of the CSA in 2012 undervalued the pre-existing intellectual property by approximately $540 million. The IRS's valuation, prepared by Dr. Washburne, applied an income method using a 7.2% discount rate and arrived at a PCT value of $852 million. The IRS contends that PPC transferred significant IP value to PBI at below-market consideration, which, when combined with the understated cost-sharing ratios, resulted in a systematic underallocation of income to the United States.
Tax year 2012 is outside the scope of the current examination (which covers only tax years 2017–2020). Nevertheless, the IRS uses the PCT undervaluation assertion as a factual predicate to support its recharacterization of the ongoing CSA cost-sharing ratios and royalty rates for the examination years. In C&H's assessment, the IRS's income-method valuation of the PCT at $852 million is unsupportable for the reasons discussed in Section V.D below, and PPC's $312 million PCT payment falls squarely within the arm's-length range established by Whitmore's independent DCF analysis.
E. Correlative Offset and Net Adjustment
The Exam Team recognized that the CSA cost-sharing adjustments and the royalty rate adjustments overlap to a degree with respect to the income allocable to PPC from PBI's non-Americas operations. To avoid double-counting, the Exam Team applied a correlative offset of ($42.65 million) to the aggregate proposed adjustments.
The net proposed adjustment is therefore calculated as follows:
CSA cost-sharing adjustments: $235.01 million Legacy IP royalty rate adjustments: $188.04 million Correlative offset: ($42.65 million) Net proposed adjustment: $380.40 million
F. Proposed Penalty
The NOPA includes a proposed penalty under Internal Revenue Code § 6662(e) for a substantial valuation misstatement in connection with a Section 482 transfer pricing allocation. The proposed penalty is calculated at 20% of the underpayment of tax attributable to the net Section 482 allocation:
Net proposed adjustment: $380.4 million Estimated federal income tax (at 21%): $79.88 million Penalty (20% of underpayment): $15.98 million (approximately)
The Exam Team reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). C&H notes that the reservation of the gross valuation misstatement penalty may reflect an intent by the Exam Team to preserve the possibility of asserting the higher penalty at a later stage, although C&H believes PPC has strong defenses against both penalty tiers, as discussed in Section VII.B below.
IV. ASC 740-10 (FIN 48) Framework
A. Two-Step Analysis
The analysis of uncertain tax positions under ASC 740-10 (formerly FIN 48) involves a two-step process that governs both whether a tax benefit is recognized in the financial statements and, if so, the amount of benefit that is recognized.
Step 1 — Recognition. Under ASC 740-10-25-6, a tax position is recognized in the financial statements only if it is "more likely than not" (i.e., a likelihood of greater than 50%) that the position will be sustained upon examination by the taxing authorities, including resolution of any related Appeals or litigation processes. The recognition determination is based solely on the technical merits of the position. The "more likely than not" standard considers the facts, circumstances, and information available at the reporting date and presumes that the taxing authority has full knowledge of all relevant information. Importantly, the recognition analysis does not consider the likelihood that a position will or will not be examined; rather, it assumes examination will occur and evaluates the probability of sustaining the position on the merits.
Step 2 — Measurement. For tax positions that meet the more-likely-than-not recognition threshold, ASC 740-10-30-7 requires that the tax benefit be measured as the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. This measurement analysis considers the amounts and probabilities of the possible outcomes that could be realized upon settlement with the taxing authority. The standard contemplates a cumulative probability approach under which each possible outcome is assigned a probability, and the cumulative probabilities are evaluated to determine the largest amount of benefit exceeding the 50% cumulative probability threshold. Under this approach, the difference between the full tax benefit claimed on the return and the measured benefit under the cumulative probability approach represents the uncertain tax position reserve.
Key authoritative guidance informing this analysis includes ASC 740-10-25-6 through 25-17 (recognition), ASC 740-10-30-7 through 30-18 (measurement), ASC 740-10-55 (implementation guidance), and the FASB Staff Positions and Technical Inquiries addressing the application of FIN 48 to transfer pricing positions. Additionally, C&H has considered the guidance in FASB ASC 740-10-50 regarding disclosure requirements for unrecognized tax benefits.
B. Application to Transfer Pricing Positions
Transfer pricing positions present unique challenges under the ASC 740-10 framework because they inherently involve ranges of arm's-length outcomes rather than binary yes-or-no determinations. Unlike many other tax positions, where the question is whether a particular treatment is correct or incorrect, transfer pricing disputes typically involve disagreements over where within the arm's-length range the appropriate price or allocation falls. Accordingly, the ASC 740-10 analysis for transfer pricing positions must consider the entire range of possible outcomes and their associated probability weightings, rather than evaluating a single all-or-nothing outcome.
The issuance of a NOPA is a significant event that must be evaluated in connection with the reporting-date assessment of uncertain tax positions. However, the issuance of a NOPA does not automatically require a change in either the recognition or the measurement conclusion previously reached. A NOPA reflects the IRS examination team's initial proposed position and is not a final determination of tax liability. In many cases — and particularly in complex transfer pricing disputes — the NOPA represents the IRS's maximum opening position, which is subject to significant reduction through the Appeals process, negotiated settlement, or, if necessary, litigation.
In evaluating the impact of the NOPA on PPC's uncertain tax position reserve, C&H has considered the following factors:
(i) the strength of PPC's technical positions on each issue raised in the NOPA;
(ii) the quality of PPC's contemporaneous transfer pricing documentation, including the penalty protection documentation prepared by Crestfield & Associates;
(iii) the comparable data supporting PPC's arm's-length pricing (CUT analysis, CPM/TNMM benchmarking, and DCF valuation);
(iv) PBI's demonstrated economic substance as an IP owner, commercial principal, and CSA participant;
(v) historical IRS settlement patterns in transfer pricing cases, including settlement rates at Appeals and in Tax Court litigation;
(vi) the likelihood of a favorable outcome at IRS Appeals, where Appeals Officers are required to consider the hazards of litigation in evaluating proposed adjustments; and
(vii) applicable case law addressing CSA cost-sharing, CUT methodology, pharmaceutical IP valuation, and economic substance in the transfer pricing context.
Each of these factors is addressed in the position-by-position analysis set forth in Sections V and VI below.
V. Updated Recognition Analysis (Step 1) — Position-by-Position
A. CSA Cost-Sharing Ratios
PPC's Position. PPC's cost-sharing percentages of 38.2% (2017), 39.6% (2018), 41.1% (2019), and 42.7% (2020) were determined based on projections of PBI's reasonably anticipated benefits relative to PPC's reasonably anticipated benefits from the intangible property developed under the CSA. These projections were prepared in accordance with the requirements of Treasury Regulation § 1.482-7(e) and were documented contemporaneously by Crestfield & Associates in PPC's annual transfer pricing reports.
C&H's Assessment of Technical Merits. C&H has conducted a detailed assessment of the technical merits of PPC's CSA cost-sharing positions, drawing upon the economic analyses prepared by Whitmore Valuation Group and the contemporaneous documentation prepared by Crestfield & Associates. The key pillars of C&H's assessment are as follows:
Economic Analysis — CPM/TNMM Benchmarking. Whitmore prepared a comprehensive comparable profits method ("CPM") and transactional net margin method ("TNMM") analysis that tested PBI's operating margins against a set of 22 comparable distributors and IP-holding companies in the pharmaceutical and life sciences sectors. The benchmarking analysis demonstrated that PBI's operating margins fell within the interquartile range of the comparable set in all four tax years at issue. This result indicates that PBI's profitability was consistent with arm's-length returns and supports the conclusion that the CSA cost-sharing ratios appropriately allocated the R&D cost pool between PPC and PBI.
Revenue Projection Methodology. PPC's RAB projections were prepared using a methodology that is consistent with the requirements of Treasury Regulation § 1.482-7(e)(2)(ii) and that reflects the relative revenue expectations of the PPC and PBI intangible development areas. The projections were based on product-by-product revenue forecasts that were consistent with PPC's contemporaneous budgeting and strategic planning processes. C&H has reviewed PPC's projection methodology in detail and has confirmed that it is reasonable, internally consistent, and adequately documented.
Case Law Support. C&H's analysis of relevant case law supports PPC's CSA methodology. In Altera Corp. v. Commissioner, 145 T.C. No. 3 (2015), aff'd, 926 F.3d 1061 (9th Cir. 2019), the Ninth Circuit upheld Treasury regulations requiring the inclusion of stock-based compensation costs in CSA cost pools, but the decision did not disturb the fundamental RAB methodology for determining cost-sharing percentages. In Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), the Eighth Circuit addressed the proper application of the comparable profits method in a medical device transfer pricing case, emphasizing the importance of selecting appropriate comparables and applying reliable methodologies. Both decisions reinforce the analytical framework that PPC has applied in determining its CSA cost-sharing ratios.
Deficiencies in the IRS's Analysis. C&H and Whitmore have identified significant deficiencies in the economic analysis prepared by Dr. Washburne in support of the IRS's proposed adjustments. Specifically, Dr. Washburne's analysis relies on different revenue projections that assume a higher proportion of value creation in the United States than is supported by PPC's contemporaneous business records. Dr. Washburne's analysis also incorporates aggressive assumptions regarding the allocation of U.S.-source value, including the attribution of value to U.S.-based research scientists that fails to adequately account for the commercial and regulatory contributions made by PBI's employees in Ireland. Furthermore, Dr. Washburne's proposed increases of 10.0 to 11.2 percentage points would result in PBI bearing a disproportionately large share of the R&D cost pool relative to its share of anticipated benefits — an outcome that is inconsistent with the arm's-length standard and with the commensurate-with-income requirement of IRC § 482.
Conclusion. Based on C&H's assessment of the technical merits, PPC's CSA cost-sharing positions for tax years 2017–2020 are more likely than not to be sustained upon examination, including resolution through Appeals or litigation. The recognition threshold under ASC 740-10-25-6 is met, and the CSA cost-sharing tax benefit should continue to be recognized in PPC's financial statements.
B. Legacy IP Royalty Rate (4.5%)
PPC's Position. PPC's 4.5% royalty rate for the legacy IP license is supported by a CUT analysis that identified 14 comparable uncontrolled pharmaceutical license agreements involving intellectual property of similar type, stage of lifecycle, therapeutic relevance, and geographic scope. The interquartile range of the 14 comparables was 3.1% to 6.8%, with a median of 4.4%.
C&H's Assessment of Technical Merits. C&H has conducted a detailed assessment of PPC's royalty rate position, focusing on the comparability of the CUT data and the reliability of the best method analysis.
CUT Analysis. PPC's 4.5% royalty rate falls squarely within the interquartile range of 3.1% to 6.8% established by the 14 comparable agreements and is virtually at the median of 4.4%. Under Treasury Regulation § 1.482-1(e)(2)(iii)(B), when a taxpayer's results fall within the interquartile range, no adjustment is warranted. PPC's rate is not merely within the range — it is at the statistical center of the comparable data, which provides an exceptionally strong defense against any proposed adjustment.
Deficiencies in the IRS's CUT Data. The IRS's proposed 11.0% royalty rate is well above the interquartile range established by PPC's CUT analysis and, indeed, above the maximum of the range. The IRS's CUT comparables, which C&H and Whitmore have reviewed, are distinguishable from PPC's legacy IP license on multiple comparability grounds, including:
(a) Therapeutic Area. Several of the IRS's CUT comparables involve licensing agreements for oncology or specialty therapeutics with significantly different risk profiles and revenue potential than PPC's legacy compounds, which are mature products facing generic competition;
(b) Product Lifecycle Stage. A number of the IRS's CUT comparables involve licenses for products at earlier stages of their lifecycle (including pre-approval or early-launch products), where royalty rates are typically higher to reflect greater revenue upside and risk sharing, compared to PPC's legacy compounds that were well past peak sales;
(c) Geographic Scope. Certain of the IRS's CUT comparables involve global or U.S.-only licenses, which are not directly comparable to PPC's non-Americas-only license; and
(d) Bundled Rights. Several IRS comparables include bundled rights to manufacturing technology, co-promotion arrangements, or exclusive supply agreements that are not present in PPC's legacy IP license.
Best Method Rule. Under Treasury Regulation § 1.482-4 and the best method rule of § 1.482-1(c), the CUT method is the most reliable method for determining the arm's-length royalty rate when sufficiently comparable uncontrolled transactions are available. PPC's CUT analysis satisfies the comparability requirements, and the IRS has not demonstrated that an alternative method would provide a more reliable measure of the arm's-length result.
Conclusion. PPC's legacy IP royalty rate of 4.5% is more likely than not to be sustained on the merits. The recognition threshold under ASC 740-10-25-6 is met, and the royalty rate tax benefit should continue to be recognized.
C. PBI Economic Substance
PPC's Position. PBI has sufficient economic substance to function as the IP owner and CSA participant for PPC's non-Americas operations. PBI performs meaningful DEMPE functions, employs significant personnel in Ireland, maintains independent governance and decision-making, and bears genuine entrepreneurial risk in connection with the non-Americas commercialization of PPC's products.
C&H's Assessment. C&H has conducted a thorough assessment of PBI's economic substance, drawing upon the functional analysis prepared jointly by C&H and Whitmore, interviews with PBI personnel, and review of PBI's governance and operational records. The key indicia of PBI's economic substance include:
(a) Headcount and Personnel. PBI employed 185 individuals as of fiscal year 2020, representing a substantial increase from 52 employees at inception in 2012. PBI's employees include senior executives, regulatory affairs professionals, medical affairs personnel, commercial strategists, supply chain managers, finance and accounting staff, and legal and compliance personnel. The growth from 52 to 185 employees over the relevant period demonstrates a deliberate and sustained investment in building operational capability in Ireland.
(b) Independent Governance. PBI's board of directors held 42 board meetings during the period 2017–2020, all of which were convened and held in Dublin, Ireland. Board meeting minutes document substantive deliberations on strategic, commercial, financial, and regulatory matters, including product launch decisions, pricing strategies, distributor selection, and capital expenditure approvals. PBI's Managing Director, Aidan Naughton, is based in Dublin and exercises day-to-day operational authority over PBI's commercial activities.
(c) Physical Presence. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, which serves as the operational headquarters for PBI's non-Americas commercial activities.
(d) Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the years at issue, reflecting PBI's direct involvement in obtaining and maintaining marketing authorizations, managing pharmacovigilance obligations, and engaging with regulatory authorities in PBI's markets.
(e) Independent Commercial Decision-Making. PBI independently manages pricing decisions across 68 country markets in its territory, including negotiations with national health authorities, reimbursement agencies, and hospital formulary committees. PBI's pricing decisions are made by PBI's commercial team in Dublin, with input from in-country affiliates, and are not directed by PPC's U.S. headquarters.
(f) Independent Banking. PBI maintains independent banking relationships with Glenmore Bank Ireland plc, through which PBI manages its own treasury operations, intercompany settlements, and cash management.
(g) DEMPE Functions. C&H's functional analysis, prepared with Whitmore, documented PBI's performance of significant DEMPE functions, including: regulatory strategy and execution, medical affairs and key opinion leader engagement, commercial strategy development, supply chain management (including oversight of contract manufacturing at PMI), market risk assessment and management, and distribution partner selection and management across 68 markets.
(h) Employee Interviews. C&H and Whitmore conducted interviews with 12 key PBI employees across multiple functional areas. These interviews corroborated PBI's independent decision-making authority and the substantive nature of PBI's operational activities.
The IRS's assertion that PBI lacked sufficient economic substance is, in C&H's assessment, contradicted by the extensive evidence of PBI's personnel, governance, infrastructure, and functional activities. While certain high-level strategic decisions and research activities are naturally centered in the United States at PPC's headquarters, PBI's non-Americas commercialization activities represent a genuine and substantial operational role that independently generates significant value.
Conclusion. PBI's economic substance is well-established, and the IRS's challenge to PBI's substance is more likely than not to fail upon examination, Appeals, or litigation. The recognition threshold under ASC 740-10-25-6 is met.
D. PCT Valuation ($312M)
PPC's Position. The PCT payment of $312 million at the inception of the CSA in July 2012 reflected the arm's-length value of PBI's buy-in to PPC's pre-existing intellectual property. Although tax year 2012 is outside the scope of the current examination (which covers only 2017–2020), the IRS uses the PCT undervaluation assertion as a factual basis for its recharacterization of the ongoing CSA cost-sharing ratios and royalty rates.
C&H's Assessment. Whitmore prepared a comprehensive discounted cash flow ("DCF") analysis of the pre-existing IP contributed to the CSA, using a weighted average cost of capital ("WACC") of 9.8%, which reflects the pharmaceutical-industry cost of capital adjusted for the specific risk profile of PPC's pre-2012 compound portfolio. Whitmore's DCF analysis produced an arm's-length range for the PCT payment of $278 million to $361 million. PPC's actual PCT payment of $312 million falls comfortably within this range, at approximately the midpoint.
The IRS's income-method valuation of $852 million is based on a 7.2% WACC that C&H and Whitmore contend is inappropriately low for pharmaceutical intellectual property. Specifically:
(a) The IRS's 7.2% discount rate reflects an insufficient risk premium for pharmaceutical IP, which is subject to significant clinical, regulatory, competitive, and market risks;
(b) Dr. Washburne's beta comparables are drawn from large-cap diversified pharmaceutical companies that are not appropriate proxies for the risk profile of a focused specialty pharmaceutical IP portfolio;
(c) The IRS's discount rate fails to reflect the pharmaceutical-industry-specific cost of capital, which academic literature and industry surveys consistently place in the range of 9% to 12% for mature pharmaceutical IP; and
(d) Applying PPC's 9.8% WACC — which is consistent with independent industry data — to the same cash flow projections used by the IRS would substantially reduce the IRS's valuation and bring it into alignment with PPC's reported range.
Conclusion. PPC's PCT valuation of $312 million is more likely than not to be sustained on the merits. The recognition threshold under ASC 740-10-25-6 is met.
E. Overall Recognition Conclusion
Based on the position-by-position analysis set forth above, C&H concludes that all four transfer pricing positions — CSA cost-sharing ratios, legacy IP royalty rate, PBI economic substance, and PCT valuation — continue to meet the more-likely-than-not recognition threshold prescribed by ASC 740-10-25-6. The issuance of the NOPA does not change C&H's assessment of the technical merits of PPC's positions.
While the NOPA represents a significant development in the examination process and reflects the Exam Team's fully articulated position on each issue, C&H's analysis demonstrates that PPC's transfer pricing positions are well-supported by contemporaneous documentation, reliable economic analyses, applicable regulatory authority, and relevant case law. The IRS's positions, by contrast, rely on aggressive assumptions, non-comparable data, and an inadequate discount rate that are unlikely to be sustained upon independent review by an Appeals Officer or, if necessary, by a court.
Accordingly, PPC should continue to recognize the full tax benefit of its transfer pricing positions in its financial statements, subject to the measurement analysis set forth in Section VI below.
VI. Updated Measurement Analysis (Step 2) — Probability-Weighted Outcomes
A. Methodology
Having determined that PPC's transfer pricing positions meet the more-likely-than-not recognition threshold, the analysis proceeds to the measurement step under ASC 740-10-30-7. The measurement step requires determining the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the IRS.
C&H applies the cumulative probability approach to this determination. Under this approach, each possible outcome of the dispute is assigned a probability based on C&H's assessment of the likelihood of that outcome occurring, considering the technical merits of the positions, the quality of the evidence, applicable law, and historical settlement patterns. The outcomes are then arrayed from the most favorable to the least favorable from PPC's perspective, and the cumulative probabilities are computed. The largest amount of benefit at which the cumulative probability exceeds 50% represents the amount to be recognized in the financial statements.
In developing the probability-weighted assessment, C&H has considered the full range of possible outcomes, spanning from a full sustain of PPC's positions (i.e., no adjustment) to a full concession of the IRS's proposed adjustments ($380.4 million). The most probable outcomes, in C&H's assessment, lie between these extremes and are informed by the following factors:
(a) Documentation Quality. PPC's contemporaneous transfer pricing documentation, prepared by Crestfield & Associates for all four tax years, is comprehensive, well-organized, and compliant with Treasury Regulation requirements. High-quality documentation strengthens the taxpayer's negotiating position and reduces the likelihood of a large adverse adjustment.
(b) Economic Analysis. The economic analyses prepared by Whitmore, including the CPM/TNMM benchmarking (22 comparables), the CUT analysis (14 comparables), and the DCF valuation ($278M–$361M range at 9.8% WACC), are robust and well-supported.
(c) IRS Appeals Settlement Patterns. Based on C&H's experience and publicly available data, transfer pricing cases that proceed to IRS Appeals routinely settle at a fraction of the proposed adjustment, particularly where the taxpayer presents contemporaneous documentation and well-supported economic analyses. Settlement rates of 15% to 30% of the proposed adjustment are not uncommon in cases with facts similar to PPC's.
(d) IRS Litigation Win Rates. In cases that proceed to Tax Court, the IRS's success rate in Section 482 transfer pricing cases is mixed, and courts have frequently rejected aggressive IRS positions in cases involving pharmaceutical IP and CSA cost-sharing.
B. Probability-Weighted Assessment by Issue
1. CSA Cost-Sharing Adjustments ($235.01M Proposed)
C&H has assessed the range of possible outcomes for the CSA cost-sharing adjustments as follows:
The full sustain outcome reflects the possibility that the IRS's proposed adjustments are entirely rejected at Appeals or in litigation. The minor adjustment outcome, which carries the highest individual probability, reflects the most likely settlement scenario in which the IRS achieves a modest concession on the cost-sharing percentages — for example, an increase of 1 to 2 percentage points rather than the proposed 10 to 11 percentage points. The moderate adjustment outcome reflects a less likely scenario in which the IRS obtains a more significant concession. The substantial adjustment outcome, which carries the lowest probability, reflects the unlikely scenario in which the IRS prevails on a majority of its proposed increase.
Based on this probability distribution, the weighted expected adjustment range for the CSA cost-sharing issue is approximately $25 million to $40 million.
2. Royalty Rate Adjustments ($188.04M Proposed)
C&H has assessed the range of possible outcomes for the royalty rate adjustments as follows:
The full sustain outcome carries a somewhat higher probability for the royalty rate issue than for the CSA issue, reflecting the strength of PPC's CUT analysis and the fact that PPC's 4.5% rate is at the median of the comparable data. The minor adjustment outcome reflects a settlement in which the royalty rate is increased modestly to 5.0% or 5.5%, which would result in a relatively small additional royalty payment. The moderate and substantial adjustment outcomes carry progressively lower probabilities.
Based on this probability distribution, the weighted expected adjustment range for the royalty rate issue is approximately $15 million to $30 million.
3. Economic Substance / PBI Recharacterization
The IRS's economic substance challenge to PBI does not represent a standalone numerical adjustment but rather serves as the theoretical underpinning for both the CSA and royalty adjustments. If the IRS were to prevail fully on its economic substance argument, it could support a complete recharacterization of the intercompany arrangements that would effectively eliminate PBI as a separate economic actor and allocate all income to PPC in the United States. However, C&H assesses the probability of the IRS prevailing on a full recharacterization as very low (5–10%), given the extensive evidence of PBI's substance documented in Section V.C above.
Because the economic substance issue is embedded in and supports the CSA and royalty adjustments, its resolution is reflected in the probability assessments set forth above rather than as a separate adjustment item.
4. Correlative Offset
In any settlement scenario, a correlative offset would apply to avoid double-counting between the CSA and royalty adjustments, consistent with the Exam Team's recognition of a ($42.65 million) offset in the NOPA. The magnitude of the correlative offset would vary depending on the specific settlement terms but would serve to reduce the total adjustment below the sum of the individual CSA and royalty adjustments.
C. Overall Measurement Conclusion
Applying the cumulative probability approach across both the CSA cost-sharing and royalty rate issues, and accounting for the expected correlative offset, C&H concludes that the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement supports a reserve in the range of approximately $55 million to $70 million.
PPC's current FIN 48 reserve of $62.4 million falls comfortably within this range and remains appropriate as of the November 20, 2023 assessment date.
Accordingly, C&H recommends no material adjustment to the $62.4 million reserve at this time. The reserve adequately reflects the probability-weighted range of outcomes and is consistent with the requirements of ASC 740-10-30-7.
VII. Impact of NOPA on Reserve Adequacy
A. Why the NOPA Does Not Require a Reserve Increase
While the issuance of the NOPA is a significant event in the examination process, C&H has concluded that it does not warrant an increase in PPC's FIN 48 reserve for the following reasons:
The NOPA Represents the IRS's Maximum Opening Position. As a matter of standard IRS examination practice, the NOPA reflects the Exam Team's maximum proposed adjustment, which serves as the starting point for further administrative proceedings rather than as a predictor of final resolution. The Exam Team's proposed adjustments of $380.4 million represent the upper boundary of the IRS's negotiating range, not the expected outcome of the dispute. In C&H's experience representing taxpayers in transfer pricing disputes, the NOPA amount bears little correlation to the ultimate resolution amount.
The Case Will Proceed to IRS Appeals. Following PPC's filing of the Protest on December 22, 2023, the case will be referred to the IRS Office of Appeals for consideration. The case has been assigned to Appeals Officer Noreen Castañeda, with the Appeals conference anticipated in early 2024. At Appeals, Officer Castañeda will conduct an independent hazards-of-litigation assessment, evaluating the strengths and weaknesses of both the IRS's and PPC's positions. Appeals Officers are required to consider the hazards of litigation and are empowered to settle cases at amounts that reflect those hazards. In C&H's experience, transfer pricing cases at Appeals routinely settle at a fraction of the proposed adjustment — often in the range of 15% to 30% of the NOPA amount — particularly where the taxpayer has contemporaneous documentation and well-supported economic analyses.
PPC's Documentation and Economic Analyses Are Strong. As detailed throughout this memorandum, PPC's transfer pricing positions are supported by contemporaneous documentation prepared by Crestfield & Associates, comprehensive economic analyses prepared by Whitmore Valuation Group (including CPM/TNMM benchmarking with 22 comparables, CUT analysis with 14 comparables, and DCF valuation at 9.8% WACC producing a range of $278M–$361M), and the demonstrated economic substance of PBI. These materials provide PPC with a strong factual and analytical foundation for the Protest and Appeals conference.
PPC's Protest Presents Strong Defenses. The formal Protest being filed on December 22, 2023 presents detailed factual and legal defenses on each issue raised in the NOPA, including the CSA cost-sharing ratios, the royalty rate, PBI's economic substance, and the PCT valuation. The Protest incorporates the economic analyses of Whitmore and the legal analysis of C&H, and C&H is confident that the Protest presents a compelling case for a resolution significantly below the NOPA amount.
B. Penalty Considerations
The IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million (20% of the underpayment attributable to the proposed $380.4 million Section 482 allocation). In addition, the Exam Team reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h).
C&H has assessed PPC's exposure to the proposed penalty and concludes that the likelihood of the penalty being sustained is low for the following reasons:
(a) Reasonable Cause Defense. PPC has a strong reasonable cause defense under IRC § 6662(e)(3)(B), which provides that no penalty shall be imposed with respect to a Section 482 transfer pricing allocation if the taxpayer establishes that: (i) the pricing was determined in accordance with a reasonable application of a specified section 482 method; (ii) the taxpayer has contemporaneous documentation establishing that its method was reasonable; and (iii) the taxpayer provided the documentation to the IRS within 30 days of a request. PPC satisfies all three elements: its pricing was determined using CUT, CPM/TNMM, and income-method analyses that constitute specified section 482 methods; Crestfield & Associates prepared contemporaneous documentation for all four tax years; and PPC has produced the documentation to the Exam Team in response to IDRs.
(b) Contemporaneous Documentation. The contemporaneous transfer pricing documentation prepared by Crestfield & Associates for tax years 2017–2020 is comprehensive, professionally prepared, and compliant with the penalty protection requirements of Treasury Regulation § 1.6662-6. This documentation provides robust penalty protection under IRC § 6662(e)(3)(B).
(c) Appeals Practice. In C&H's experience, the IRS Office of Appeals routinely abates transfer pricing penalties where the taxpayer demonstrates reasonable cause through contemporaneous documentation, even in cases where some portion of the underlying transfer pricing adjustment is sustained.
Based on this assessment, C&H recommends no additional reserve for penalty exposure.
C. Tax Rate Considerations
The applicable federal corporate income tax rate varied across the examination years due to the enactment of the Tax Cuts and Jobs Act ("TCJA"), which reduced the corporate rate from 35% to 21% effective January 1, 2018:
• Tax Year 2017: The U.S. corporate income tax rate was 35% for the full year. However, given that the allocation to 2017 in settlement scenarios represents a relatively smaller portion of the overall adjustment (approximately $11.2 million in the expected settlement range), the blended tax impact of the 2017 rate differential is modest.
• Tax Years 2018–2020: The applicable rate is 21%, which constitutes the dominant portion of the adjustment period and the primary basis for the reserve calculation.
For measurement purposes, the $62.4 million reserve reflects the 21% rate applicable to 2018–2020 as the dominant component of the adjustment period, with an appropriate adjustment for the 2017 rate differential.
C&H has also analyzed the impact of the Global Intangible Low-Taxed Income ("GILTI") provisions under IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") provisions under IRC § 59A, both of which were enacted by the TCJA and apply to tax years 2018–2020. The GILTI and BEAT analyses have been conducted separately and do not materially change the reserve calculation, as the potential interactions between any Section 482 adjustment and PPC's GILTI and BEAT computations are relatively modest and are within the range of uncertainty already reflected in the reserve.
D. Foreign Tax Credit and Competent Authority Considerations
Any adjustment to PPC's U.S. taxable income arising from a Section 482 allocation may give rise to economic double taxation — that is, the same income being taxed both in the United States (as a result of the Section 482 adjustment) and in Ireland (as income reported by PBI for Irish tax purposes). The U.S.-Ireland Income Tax Treaty provides a mechanism to address such double taxation through the Mutual Agreement Procedure ("MAP") under Article 25 of the Treaty.
If a final Section 482 adjustment is sustained (whether through settlement at Appeals or through litigation), PPC may request that the U.S. Competent Authority initiate MAP proceedings with the Irish Revenue Commissioners to obtain a correlative adjustment in Ireland, thereby eliminating or reducing the double taxation. A successful MAP resolution could result in a refund of Irish taxes paid by PBI on the income reallocated to PPC.
However, this potential relief is not factored into the FIN 48 reserve at this time, as it is uncertain and contingent upon future proceedings. The MAP process is discretionary, and the outcome of any MAP negotiation between the U.S. and Irish competent authorities cannot be predicted with sufficient reliability to be reflected in the measurement analysis.
C&H notes that PPC has retained Thornbury & Keogh (Ciarán Thornbury, Lead Partner; 22 Fitzwilliam Square, Dublin 2, Ireland) to monitor the Irish Revenue implications of the U.S. examination and to advise on the availability and mechanics of the MAP. Thornbury & Keogh is being kept apprised of developments in the U.S. proceedings and is prepared to engage with the Irish Revenue Commissioners as appropriate.
VIII. Comparison to Initial September 2022 Analysis
C&H's initial FIN 48 analysis, dated September 2022, established the $62.4 million uncertain tax position reserve based on C&H's estimated probability of an IRS challenge to PPC's CSA and royalty positions, the likely magnitude of any such challenge, and the probability-weighted range of outcomes upon ultimate resolution. The September 2022 analysis was prepared at a time when the IRS examination was in its early stages and the specific nature and magnitude of the IRS's proposed adjustments were not yet known.